Literature DB >> 12458977

A meta-analysis of utility estimates for HIV/AIDS.

Tammy O Tengs1, Ting H Lin.   

Abstract

The authors performed a meta-analysis to derive pooled utilities for HIV/AIDS and to assess the relative importance of study design characteristics in predicting utilities. Twenty-five articles were identified reporting 74 unique utilities elicited from 1956 respondents. The authors used a hierarchical linear model to perform the meta-analysis, with disease stage, elicitation method, respondent type, and the upper-bound and lower-bound labels for the utility scale as the independent variables. Disease stage (P = 0.016) and respondent type (P = 0.014) were significant predictors of utility. Elicitation method was of marginal significance (P = 0. 052). Bounds were not significant. Pooling utilities, the authors estimate a utility of 0.70 for AIDS, 0.82 for symptomatic HIV and 0.94 for asymptomatic HIV when the time tradeoff method is used to elicit utilities from patients and the scale ranges from death to perfect health. The pooled utilities reported here should be of great use to researchers performing cost-utility analyses of interventions for HIV/AIDS.

Entities:  

Mesh:

Year:  2002        PMID: 12458977     DOI: 10.1177/0272989X02238300

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  66 in total

1.  The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Authors:  Elisa F Long; Douglas K Owens
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

2.  The effect of diagnosis with HIV infection on health-related quality of Life.

Authors:  Shyoko Honiden; Vandana Sundaram; Robert F Nease; Mark Holodniy; Laura C Lazzeroni; Andrew Zolopa; Douglas K Owens
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

3.  Measuring Population Health in a Large Integrated Health System to Guide Goal Setting and Resource Allocation: A Proof of Concept.

Authors:  Elizabeth R Stevens; Qinlian Zhou; Kimberly A Nucifora; Glen B Taksler; Marc N Gourevitch; Matthew C Stiefel; Patricia Kipnis; R Scott Braithwaite
Journal:  Popul Health Manag       Date:  2018-12-04       Impact factor: 2.459

4.  Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda.

Authors:  Joseph B Babigumira; Ajay K Sethi; Kathleen A Smyth; Mendel E Singer
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  The burden of age-related macular degeneration: a value-based medicine analysis.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2005

6.  Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Authors:  Ashley A Leech; James F Burgess; Meg Sullivan; Wendy Kuohung; Michal Horný; Mari-Lynn Drainoni; Cindy L Christiansen; Benjamin P Linas
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

7.  Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.

Authors:  Ru Han; Clément François; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

8.  The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Authors:  Blythe Adamson; Wafaa El-Sadr; Dobromir Dimitrov; Theresa Gamble; Geetha Beauchamp; Josh J Carlson; Louis Garrison; Deborah Donnell
Journal:  Value Health       Date:  2018-11-02       Impact factor: 5.725

9.  Is the US AIDS drug assistance program cost-effective?

Authors:  Steven D Pinkerton; Jennifer Kibicho; Carol L Galletly
Journal:  AIDS Behav       Date:  2013-01

10.  Cost-effectiveness of newborn circumcision in reducing lifetime HIV risk among U.S. males.

Authors:  Stephanie L Sansom; Vimalanand S Prabhu; Angela B Hutchinson; Qian An; H Irene Hall; Ram K Shrestha; Arielle Lasry; Allan W Taylor
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.